Savior Lifetec (4167) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.026x

Based on the latest financial reports, Savior Lifetec (4167) has a cash flow conversion efficiency ratio of -0.026x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-98.65 Million ≈ $-3.11 Million USD) by net assets (NT$3.78 Billion ≈ $119.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Savior Lifetec liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Savior Lifetec - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Savior Lifetec's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Savior Lifetec Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Savior Lifetec ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
X-Legend Entertainment Co Ltd
TW:4994
0.036x
Eastern Media International Corp
TW:2614
0.080x
AMIA Co. Ltd.
TW:8438
0.062x
TriSalus Life Sciences Inc.
NASDAQ:TLSI
0.139x
AgriFORCE Growing Systems Ltd
NASDAQ:AGRI
-0.196x
Inversora Juramento SA
BA:INVJ
-0.033x
Deep Value Driller AS
OL:DVD
0.957x
Bang & Olufsen
CO:BO
0.041x

Annual Cash Flow Conversion Efficiency for Savior Lifetec (2011–2025)

The table below shows the annual cash flow conversion efficiency of Savior Lifetec from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see 4167 company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 NT$3.78 Billion
≈ $119.12 Million
NT$-21.04 Million
≈ $-662.91K
-0.006x -103.77%
2024-12-31 NT$3.52 Billion
≈ $110.78 Million
NT$518.38 Million
≈ $16.33 Million
0.147x +27.87%
2023-12-31 NT$3.36 Billion
≈ $106.01 Million
NT$387.95 Million
≈ $12.22 Million
0.115x -33.27%
2022-12-31 NT$3.37 Billion
≈ $106.08 Million
NT$581.77 Million
≈ $18.33 Million
0.173x +440.04%
2021-12-31 NT$3.31 Billion
≈ $104.37 Million
NT$-168.34 Million
≈ $-5.30 Million
-0.051x -285.45%
2020-12-31 NT$3.33 Billion
≈ $104.92 Million
NT$91.25 Million
≈ $2.87 Million
0.027x -61.21%
2019-12-31 NT$2.21 Billion
≈ $69.75 Million
NT$156.40 Million
≈ $4.93 Million
0.071x +169.06%
2018-12-31 NT$1.86 Billion
≈ $58.47 Million
NT$-189.84 Million
≈ $-5.98 Million
-0.102x -184.82%
2017-12-31 NT$2.16 Billion
≈ $68.15 Million
NT$260.89 Million
≈ $8.22 Million
0.121x +435.93%
2016-12-31 NT$2.12 Billion
≈ $66.77 Million
NT$-76.09 Million
≈ $-2.40 Million
-0.036x +86.25%
2015-12-31 NT$1.59 Billion
≈ $50.15 Million
NT$-415.82 Million
≈ $-13.10 Million
-0.261x -265.61%
2014-12-31 NT$1.29 Billion
≈ $40.75 Million
NT$-92.41 Million
≈ $-2.91 Million
-0.071x -16.66%
2013-12-31 NT$1.39 Billion
≈ $43.93 Million
NT$-85.39 Million
≈ $-2.69 Million
-0.061x +65.70%
2012-12-31 NT$1.27 Billion
≈ $40.16 Million
NT$-227.59 Million
≈ $-7.17 Million
-0.179x +48.89%
2011-12-31 NT$1.31 Billion
≈ $41.38 Million
NT$-458.82 Million
≈ $-14.46 Million
-0.349x --

About Savior Lifetec

TWO:4167 Taiwan Biotechnology
Market Cap
$194.15 Million
NT$6.16 Billion TWD
Market Cap Rank
#16753 Global
#835 in Taiwan
Share Price
NT$19.85
Change (1 day)
+0.00%
52-Week Range
NT$17.00 - NT$21.85
All Time High
NT$40.63
About

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more